{"id":27357,"date":"2024-03-19T14:22:26","date_gmt":"2024-03-19T08:52:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27357"},"modified":"2024-03-19T14:22:28","modified_gmt":"2024-03-19T08:52:28","slug":"pharma-news-for-bms-orchard-madrigal-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca","title":{"rendered":"Bristol Myers Squibb\u2019 Karuna Therapeutics Buyout; Orchard Therapeutics\u2019 Lenmeldy FDA Approval; Madrigal Pharmaceuticals\u2019 Rezdiffra FDA Approval; AstraZeneca\u2019s Acquisition of Amolyt Pharma; Prilenia\u2019s Pridopidine EU Marketing Approval"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2e4523187\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2e4523187\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\/#Bristol_Myers_Squibb_Enhances_Neuroscience_Arm_with_Karuna_Therapeutics_Buyout\" >Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\/#FDA_Greenlights_Orchard_Therapeutics_Lenmeldy_for_Young_Patients_with_Metachromatic_Leukodystrophy\" >FDA Greenlights Orchard Therapeutics\u2019 Lenmeldy for Young Patients with Metachromatic Leukodystrophy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\/#Madrigal_Pharmaceuticals_Rezdiffra_Secures_FDA_Approval_for_Noncirrhotic_NASH_with_Moderate_to_Advanced_Liver_Fibrosis_Treatment\" >Madrigal Pharmaceuticals\u2019 Rezdiffra Secures FDA Approval for Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\/#AstraZenecas_Acquisition_of_Amolyt_Pharma_Boosts_Advancements_in_Late-Stage_Rare_Disease_Treatments\" >AstraZeneca\u2019s Acquisition of Amolyt Pharma Boosts Advancements in Late-Stage Rare Disease Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\/#Prilenia_Aims_for_EU_Marketing_Approval_of_Pridopidine_for_Huntingtons_Disease\" >Prilenia Aims for EU Marketing Approval of Pridopidine for Huntington\u2019s Disease<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-bristol-myers-squibb-enhances-neuroscience-arm-with-karuna-therapeutics-buyout\"><span class=\"ez-toc-section\" id=\"Bristol_Myers_Squibb_Enhances_Neuroscience_Arm_with_Karuna_Therapeutics_Buyout\"><\/span><strong>Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bristol Myers Squibb<\/strong> has declared the finalization of its purchase of <strong>Karuna Therapeutics, Inc.<\/strong> With this acquisition concluded Karuna\u2019s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owned by Bristol Myers Squibb.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled to broaden our range of neuroscience offerings with the addition of Karuna to Bristol Myers Squibb,\u201d stated <\/em><strong><em>Chris Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb<\/em><\/strong><em>. \u201cCrucially, this agreement supports our dedication to enhancing BMS\u2019s growth prospects for the latter part of this decade and beyond. We are eager to collaborate with the skilled team at Karuna to introduce KarXT to individuals with schizophrenia later in the current year.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Through this deal, BMS has acquired <strong>KarXT (xanomeline-trospium)<\/strong>, an antipsychotic showcasing a new method of action along with a distinctive efficacy and safety profile. Additionally, BMS has gained access to Karuna\u2019s early-stage and pre-clinical pipeline. KarXT is slated for a Prescription Drug User Fee Act (PDUFA) decision on <strong>September 26, 2024<\/strong>, specifically for treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\">schizophrenia in adults<\/a>. Furthermore, KarXT is currently undergoing trials for its use as an adjunctive therapy alongside existing standard treatments for schizophrenia, as well as for treating psychosis in <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s patients<\/a>. There is potential for its application to broaden into other conditions such as Bipolar I disorder and agitation in Alzheimer\u2019s disease.<\/p>\n\n\n\n<p>The deal will be recorded as acquiring an asset, leading to a one-time, non-deductible charge of around <strong>$12 billion<\/strong> for Acquired In-Process Research and Development (Acquired IPR&amp;D). This will affect both the first quarter and full-year 2024 GAAP and non-GAAP earnings per share by roughly <strong>$5.93<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-greenlights-orchard-therapeutics-lenmeldy-for-young-patients-with-metachromatic-leukodystrophy\"><span class=\"ez-toc-section\" id=\"FDA_Greenlights_Orchard_Therapeutics_Lenmeldy_for_Young_Patients_with_Metachromatic_Leukodystrophy\"><\/span><strong>FDA Greenlights Orchard Therapeutics\u2019 Lenmeldy for Young Patients with Metachromatic Leukodystrophy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Orchard Therapeutics<\/strong>, which was recently acquired by <strong>Kyowa Kirin <\/strong>to speed up the delivery of new gene therapies to patients worldwide, has announced that the FDA has given approval for <strong>Lenmeldy (atidarsagene autotemcel)<\/strong>, previously known as <strong>OTL-200<\/strong>. This approval is for treating children who have pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ) forms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/metachromatic-leukodystrophy-mld-market\">metachromatic leukodystrophy (MLD)<\/a>\u2014all collectively known as early-onset MLD.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Bobby Gaspar, M.D., Ph.D., co-founder and CEO of Orchard Therapeutics<\/em><\/strong><em>, expressed that the FDA\u2019s approval of Lenmeldy presents significant new opportunities for children in the U.S. facing early-onset MLD, a condition for which there were previously no treatment options beyond supportive and end-of-life care. Dr. Gaspar emphasized the severe impact of MLD, a rare disease that progresses rapidly, limits life, and is ultimately fatal, affecting children and families profoundly. He acknowledged that this achievement results from years of dedicated research and development in collaboration with the San Raffaele-Telethon Institute for Gene Therapy. Dr. Gaspar extended sincere appreciation to the patients and families involved in clinical trials, as well as to the wider MLD community, recognizing their invaluable contributions and support as pivotal to reaching this milestone.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Lenmeldy\u2019s goal is to address the root genetic cause of MLD by placing one or more fully functional copies of the human ARSA gene into a patient\u2019s own hematopoietic stem cells (HSCs) outside the body, using a lentiviral carrier. These genetically corrected cells are then reintroduced into the patient\u2019s system. Once they take hold, these cells develop into various cell types, including some that move through the blood-brain barrier into the central nervous system, where they produce the needed enzyme. This method could potentially revive enzyme function, halting or reducing the advancement of the disease with just one therapy.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/orchards-otl-200-for-mld-treatment\">Lenmeldy<\/a> received <strong>Priority Review status<\/strong> in September 2023. Before this, it had been awarded <strong>Rare Pediatric Disease (RPD) and Regenerative Medicine Advanced Therapy (RMAT) designations<\/strong> by the FDA. Orchard Therapeutics was granted a <strong>Priority Review Voucher (PRV)<\/strong> alongside the approval, which is set to be transferred to GSK as per the conditions of the initial licensing agreement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-madrigal-pharmaceuticals-rezdiffra-secures-fda-approval-for-noncirrhotic-nash-with-moderate-to-advanced-liver-fibrosis-treatment\"><span class=\"ez-toc-section\" id=\"Madrigal_Pharmaceuticals_Rezdiffra_Secures_FDA_Approval_for_Noncirrhotic_NASH_with_Moderate_to_Advanced_Liver_Fibrosis_Treatment\"><\/span><strong>Madrigal Pharmaceuticals\u2019 Rezdiffra Secures FDA Approval for Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Madrigal Pharmaceuticals, Inc.<\/strong> has reported that the FDA has given accelerated approval for <strong>Rezdiffra (resmetirom)<\/strong> when used alongside diet and exercise. This approval is for treating <a href=\"https:\/\/www.delveinsight.com\/blog\/novel-drug-classes-for-nash-treatment\">adults who have noncirrhotic NASH<\/a> with moderate to advanced liver fibrosis (corresponding to stages F2 to F3 fibrosis). Further approval for this use may depend on confirming and describing the clinical benefits in ongoing trials.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Bill Sibold, Madrigal\u2019s CEO<\/em><\/strong><em>, expressed that NASH, a liver disease marked by moderate to advanced fibrosis, has been a severe and progressing condition lacking FDA-approved treatments until now. The fast-tracked approval of Rezdiffra is the result of over 15 years of research led by Dr. Becky Taub, the company\u2019s founder, and a small research and development team. Tackling one of the most significant challenges in drug development, marks a pivotal moment for the NASH field, showcasing the potential of the industry. Sibold added that they are eager to provide Rezdiffra to patients in need.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Rezdiffra, a daily oral THR-\u03b2 agonist, is engineered to address core factors contributing to NASH. Its fast-track approval came after the <strong>Phase III MAESTRO-NASH study<\/strong>, recently published in the New England Journal of Medicine. This pivotal trial continues, involving 1,759 <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">NASH patients<\/a> confirmed through biopsy. Over 52 weeks, both the 100 mg and 80 mg Rezdiffra doses significantly outperformed a placebo on two main measures: resolving NASH (with a decrease in NAFLD activity score by \u22652 points) without worsening fibrosis and enhancing fibrosis by at least one stage without worsening NAFLD activity score. These benefits were consistent across different demographics like age, gender, presence of type 2 diabetes, or stage of fibrosis.<\/p>\n\n\n\n<p>Rezdiffra is anticipated to be accessible for US patients starting in April, with distribution managed via a restricted specialty pharmacy network. Madrigal is dedicated to assisting suitable patients who could benefit from Rezdiffra by facilitating access through the Madrigal Patient Support initiative. This initiative aims to guide patients through insurance and financial obstacles, offering co-pay aid for those eligible. Additionally, Madrigal has initiated a patient assistance program (PAP) to aid uninsured patients in obtaining access to Rezdiffra.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-astrazeneca-s-acquisition-of-amolyt-pharma-boosts-advancements-in-late-stage-rare-disease-treatments\"><span class=\"ez-toc-section\" id=\"AstraZenecas_Acquisition_of_Amolyt_Pharma_Boosts_Advancements_in_Late-Stage_Rare_Disease_Treatments\"><\/span><strong>AstraZeneca\u2019s Acquisition of Amolyt Pharma Boosts Advancements in Late-Stage Rare Disease Treatments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AstraZeneca <\/strong>has revealed its plans to buy <strong>Amolyt Pharma<\/strong>, a biotech firm in the clinical stage that concentrates on creating new therapies for rare endocrine illnesses. This acquisition aims to strengthen the Alexion and AstraZeneca Rare Disease late-stage development pipeline. It will also broaden its expertise in bone metabolism by adding <strong>eneboparatide (AZP-3601)<\/strong>, a Phase III experimental peptide with a unique way of working that targets important treatment objectives for hypoparathyroidism. Furthermore, Alexion is eager to incorporate the skilled team members from Amolyt Pharma into its fold.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Marc Dunoyer, CEO of Alexion, AstraZeneca Rare Disease<\/em><\/strong><em>, expressed that individuals with <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hypoparathyroidism-market\"><em>chronic hypoparathyroidism<\/em><\/a><em> urgently require an alternative to current supportive treatments, as these fail to address the root cause of hormone deficiency. With Alexion\u2019s expertise in rare diseases, they are well-placed to advance the late-stage development and worldwide distribution of eneboparatide. This drug has the potential to reduce the often severe effects of low parathyroid hormone levels and eliminate the risks associated with high-dose calcium supplements. Dunoyer believes that this initiative, in collaboration with Amolyt\u2019s skilled team and promising pipeline, will facilitate their expansion into the realm of rare endocrine disorders.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p><strong>Eneboparatide<\/strong>, acting as an agonist for the PTH receptor 1 (PTHR1), operates through an innovative mechanism tailored to address the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypoparathyroidism-market\">treatment objectives of hypoparathyroidism<\/a>. Phase II findings demonstrated that eneboparatide not only restored serum calcium levels to normal but also showed promise in potentially removing the need for daily calcium and vitamin D supplements. Among adults grappling with chronic hypoparathyroidism alongside hypercalciuria, eneboparatide was observed to bring about a normalization of calcium levels in urine. Furthermore, in individuals with hypoparathyroidism, eneboparatide safeguarded bone mineral density, offering a significant potential advantage for those at heightened risk of osteopenia or osteoporosis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-prilenia-aims-for-eu-marketing-approval-of-pridopidine-for-huntington-s-disease\"><span class=\"ez-toc-section\" id=\"Prilenia_Aims_for_EU_Marketing_Approval_of_Pridopidine_for_Huntingtons_Disease\"><\/span><strong>Prilenia Aims for EU Marketing Approval of Pridopidine for Huntington\u2019s Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Prilenia Therapeutics B.V.<\/strong> has revealed intentions to present a Marketing Authorization Application (MAA) for pridopidine to the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP), aiming for its <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">approval for treating Huntington\u2019s disease<\/a>. This announcement comes after productive pre-submission discussions with EU regulatory bodies, with the submission slated for mid-2024.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Dr. Michael R. Hayden, CEO of Prilenia<\/em><\/strong><em>, stated that Pridopidine consistently shows beneficial effects in various areas important to patients and their families. These include everyday functioning, cognition, motor skills, and clinical advancement in <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\"><em>individuals with Huntington&#8217;s disease<\/em><\/a><em>. The advantages are particularly clear in HD patients who do not use anti-dopaminergic medications (ADM). Hayden expressed gratitude for the productive discussions with European regulators concerning their pridopidine data. This progress offers a potential path toward approving a therapy for Huntington&#8217;s disease, a rare neurodegenerative condition marked by a predictable decline and a current lack of approved treatments that address its progression. The company is now finalizing its submission for Marketing Authorization Application (MAA) by mid-2024 and preparing to make pridopidine available for commercial use among patients in Europe, pending approval.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>ADMs encompass neuroleptics (alternatively termed antipsychotics) and VMAT2 inhibitor (anti-chorea) medications. Prilenia aims to engage in discussions with the FDA regarding potential avenues for pridopidine as a prospective treatment for individuals with Huntington&#8217;s disease in the United States. The company also plans to explore regulatory submissions globally for other countries and regions after the regulatory assessment process in Europe. Apart from advancements in Huntington&#8217;s disease, Prilenia disclosed in January 2024 that it had concluded talks with regulatory bodies worldwide concerning the next developmental phase of pridopidine for amyotrophic lateral sclerosis (ALS) and is preparing for a singular pivotal Phase III trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna\u2019s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owned by Bristol Myers Squibb. \u201cWe are thrilled to [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27358,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,21900,96,20732,305,6307,20497,21897,21898,17587,1469,1971,21300,21902,21901,21899,1519],"industry":[17225],"therapeutic_areas":[17239,17245],"class_list":["post-27357","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-amolyt-pharma","tag-astrazeneca","tag-bristol-myers-squibb-2","tag-huntingtons-disease","tag-hypoparathyroidism-therapies","tag-karuna-therapeutics","tag-lenmeldy","tag-madrigal-pharmaceuticals","tag-metachromatic-leukodystrophy","tag-nash","tag-orchard-therapeutics","tag-otl-200","tag-pridopidine","tag-prilenia","tag-resmetirom","tag-schizophrenia","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | AstraZeneca, BMS, Orchard, Madrigal<\/title>\n<meta name=\"description\" content=\"BMS\u2019 Karuna Buyout; Orchard Therapeutics\u2019 Lenmeldy; Madrigal\u2019s Rezdiffra; AstraZeneca\u2019s Amolyt Pharma Acquisition; Prilenia\u2019s Pridopidine\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | AstraZeneca, BMS, Orchard, Madrigal\" \/>\n<meta property=\"og:description\" content=\"BMS\u2019 Karuna Buyout; Orchard Therapeutics\u2019 Lenmeldy; Madrigal\u2019s Rezdiffra; AstraZeneca\u2019s Amolyt Pharma Acquisition; Prilenia\u2019s Pridopidine\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-19T08:52:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-19T08:52:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | AstraZeneca, BMS, Orchard, Madrigal","description":"BMS\u2019 Karuna Buyout; Orchard Therapeutics\u2019 Lenmeldy; Madrigal\u2019s Rezdiffra; AstraZeneca\u2019s Amolyt Pharma Acquisition; Prilenia\u2019s Pridopidine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca","og_locale":"en_US","og_type":"article","og_title":"Pharma News | AstraZeneca, BMS, Orchard, Madrigal","og_description":"BMS\u2019 Karuna Buyout; Orchard Therapeutics\u2019 Lenmeldy; Madrigal\u2019s Rezdiffra; AstraZeneca\u2019s Amolyt Pharma Acquisition; Prilenia\u2019s Pridopidine","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-03-19T08:52:26+00:00","article_modified_time":"2024-03-19T08:52:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca","name":"Pharma News | AstraZeneca, BMS, Orchard, Madrigal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca.png","datePublished":"2024-03-19T08:52:26+00:00","dateModified":"2024-03-19T08:52:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"BMS\u2019 Karuna Buyout; Orchard Therapeutics\u2019 Lenmeldy; Madrigal\u2019s Rezdiffra; AstraZeneca\u2019s Amolyt Pharma Acquisition; Prilenia\u2019s Pridopidine","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-orchard-madrigal-astrazeneca#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca.png","width":772,"height":482,"caption":"pharma-news-for-bms-orchard-madrigal-astrazeneca"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/19141337\/pharma-news-for-bms-orchard-madrigal-astrazeneca-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amolyt Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hypoparathyroidism therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Karuna Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lenmeldy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Madrigal Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Metachromatic Leukodystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orchard Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OTL-200<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pridopidine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prilenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">resmetirom<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Amolyt Pharma<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bristol Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Hypoparathyroidism therapies<\/span>","<span class=\"advgb-post-tax-term\">Karuna Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Lenmeldy<\/span>","<span class=\"advgb-post-tax-term\">Madrigal Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Metachromatic Leukodystrophy<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Orchard Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">OTL-200<\/span>","<span class=\"advgb-post-tax-term\">Pridopidine<\/span>","<span class=\"advgb-post-tax-term\">Prilenia<\/span>","<span class=\"advgb-post-tax-term\">resmetirom<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 19, 2024","modified":"Updated on Mar 19, 2024"},"absolute_dates_time":{"created":"Posted on Mar 19, 2024 2:22 pm","modified":"Updated on Mar 19, 2024 2:22 pm"},"featured_img_caption":"pharma-news-for-bms-orchard-madrigal-astrazeneca","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27357"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27357\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27358"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27357"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27357"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}